Clinical Cancer Research, Vol 4, Issue 7 1727-1736, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells

DM van der Kolk, EG de Vries, JA Koning, E van den Berg, M Muller and E Vellenga
Department of Internal Medicine, University Hospital of Groningen, The Netherlands.

To develop a functional assay for the activity of the multidrug resistance protein 1 (MRP1), we tested whether carboxyfluorescein (CF) was specifically transported by MRP and whether this transport pump could be specifically blocked by the leukotriene D4 receptor antagonist MK-571. The activity and expression of MRP1 were studied in several tumor cell lines and in leukemic blasts from patients with acute myeloid leukemia (AML). In the MRP1-overexpressing cell line GLC4/ADR and the MRP1-transfected cell line S1(MRP), MK-571 inhibited CF efflux with high factors [45.9+/-5.8 (mean+/-SD) and 14.4+/-3.2, respectively; n=3; efflux-blocking factors are defined as the ratio of the median fluorescence in presence or absence of MK-571] compared with their MRP1 low-expressing counterparts GLC4 (11.5+/-2.7) and S1 (2.8+/-0.4). In 15 AML cases, the CF efflux-blocking factors of MK-571 varied between 1.9 and 5.2. A good correlation was found between MRP1 protein expression and CF efflux-blocking factors of MK-571 (P=0.013, r=0.39). Besides MRP1, MRP2 was demonstrated with reverse transcription-PCR in 40% of the cases. In contrast to the cell lines, MK-571 also inhibited rhodamine 123 (Rh123) efflux in AML samples. On the other hand, PSC833, a P-glycoprotein specific inhibitor, did not modulate the CF efflux but is efficient in blocking Rh123 efflux. This study demonstrates that AML blasts express MRP1 and MRP2 and that MRP1 activity can be determined by a flow cytometric assay using CF and MK-571.

This article has been cited by other articles:

				S. Teng, V. Jekerle, and M. Piquette-Miller INDUCTION OF ABCC3 (MRP3) BY PREGNANE X RECEPTOR ACTIVATORS Drug Metab. Dispos., November 1, 2003; 31(11): 1296 - 1299. [Abstract] [Full Text] [PDF]

				S. L. A. Plasschaert, D. M. van der Kolk, E. S. J. M. de Bont, W. A. Kamps, K. Morisaki, S. E. Bates, G. L. Scheffer, R. J. Scheper, E. Vellenga, and E. G. E. de Vries The Role of Breast Cancer Resistance Protein in Acute Lymphoblastic Leukemia Clin. Cancer Res., November 1, 2003; 9(14): 5171 - 5177. [Abstract] [Full Text] [PDF]

				J E Ros, T A D Roskams, M Geuken, R Havinga, P L Splinter, B E Petersen, N F LaRusso, D M van der Kolk, F Kuipers, K N Faber, et al. ATP binding cassette transporter gene expression in rat liver progenitor cells Gut, July 1, 2003; 52(7): 1060 - 1067. [Abstract] [Full Text]

				D. M. van der Kolk, E. Vellenga, G. L. Scheffer, M. Muller, S. E. Bates, R. J. Scheper, and E. G. E. de Vries Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia Blood, May 15, 2002; 99(10): 3763 - 3770. [Abstract] [Full Text] [PDF]

				R. Roozendaal, E. Vellenga, M. A. de Jong, K. F. Traanberg, D. S. Postma, J. G. R. de Monchy, and H. F. Kauffman Resistance of activated human Th2 cells to NO-induced apoptosis is mediated by {{gamma}}-glutamyltranspeptidase Int. Immunol., April 1, 2001; 13(4): 519 - 528. [Abstract] [Full Text] [PDF]

				D. M. van der Kolk, E. G. E. de Vries, W. L. J. van Putten, L. F. Verdonck, G. J. Ossenkoppele, G. E. G. Verhoef, and E. Vellenga P-glycoprotein and Multidrug Resistance Protein Activities in Relation to Treatment Outcome in Acute Myeloid Leukemia Clin. Cancer Res., August 1, 2000; 6(8): 3205 - 3214. [Abstract] [Full Text]

				D. M. van der Kolk, E. Vellenga, A. Y. van der Veen, L. Noordhoek, H. Timmer-Bosscha, G. J. Ossenkoppele, R. A. Raymakers, M. Muller, E. van den Berg, and E. G. E. de Vries Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity Blood, June 1, 2000; 95(11): 3514 - 3519. [Abstract] [Full Text] [PDF]

				T. Cantz, A. T. Nies, M. Brom, A. F. Hofmann, and D. Keppler MRP2, a human conjugate export pump, is present and transports fluo 3 into apical vacuoles of Hep G2 cells Am J Physiol Gastrointest Liver Physiol, April 1, 2000; 278(4): G522 - G531. [Abstract] [Full Text] [PDF]

				H. Sietsma, R. J. Veldman, D. v. d. Kolk, B. Ausema, W. Nijhof, W. Kamps, E. Vellenga, and J. W. Kok 1-Phenyl-2-decanoylamino-3-morpholino-1-propanol Chemosensitizes Neuroblastoma Cells for Taxol and Vincristine Clin. Cancer Res., March 1, 2000; 6(3): 942 - 948. [Abstract] [Full Text]

				O. Legrand, G. Simonin, A. Beauchamp-Nicoud, R. Zittoun, and J.-P. Marie Simultaneous Activity of MRP1 and Pgp Is Correlated With In Vitro Resistance to Daunorubicin and With In Vivo Resistance in Adult Acute Myeloid Leukemia Blood, August 1, 1999; 94(3): 1046 - 1056. [Abstract] [Full Text] [PDF]

				R. Mor-Cohen, A. Zivelin, N. Rosenberg, M. Shani, S. Muallem, and U. Seligsohn Identification and Functional Analysis of Two Novel Mutations in the Multidrug Resistance Protein 2 Gene in Israeli Patients with Dubin-Johnson Syndrome J. Biol. Chem., September 28, 2001; 276(40): 36923 - 36930. [Abstract] [Full Text] [PDF]